INSP
Strong BuyUnloved QualityAI neutralInspire Medical Systems, Inc. · Healthcare · United States · $2.1B cap · $63.9M/day traded
$71.11 -2.1% · close 23 Oct · scored 24 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Report expected 2 Nov: the next-year EPS estimate has risen 21.7% over the last 14 weeks.
As of 24 Oct 2026, MoatMap's StockRank for Inspire Medical Systems, Inc. (INSP) is 82/100, ranked against 24,000+ stocks in 35 markets (Quality 80, Value 51, Momentum 48, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Inspire Medical makes an implanted nerve-stimulation device for obstructive sleep apnea in patients who cannot tolerate CPAP masks. It has high gross margins, a strong patent position and a large untreated patient pool, and the shares jumped about 23% after second-quarter results as the company worked through reimbursement changes. Speculation about a possible takeover by a larger medtech group has also appeared. The long-term concern is whether GLP-1 weight-loss drugs shrink the number of patients who need the device, and reimbursement changes are still being absorbed.
ABOUT INSPIRE MEDICAL SYSTEMS, INC.
Read
Inspire Medical Systems, Inc. is a medical technology company specializing in the development and commercialization of a minimally invasive neurostimulation device for obstructive sleep apnea (OSA). Its significant competitive moat stems from its Inspire system being the first and only FDA-approved implantable device for moderate-to-severe OSA, establishing a strong first-mover advantage. The company targets a large addressable market of patients who cannot tolerate traditional OSA therapies.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 407.9M | 624.8M | 802.8M | 912.0M | 30.8% | 898.7M | 853.9M | 887.3M | -1.4% |
| EPS | -1.60 | -0.72 | 1.80 | 4.95 | 175.0% | 4.54 | 2.56 | 3.14 | -20.3% |
| Shares | 29.0M | 29.6M | 29.7M | 28.6M | -1.5% | 28.9M | — | — | — |
| Debt | 8.9M | 24.8M | 31.8M | 32.2M | 53.6% | 29.1M | — | — | — |
| Equity | 496.0M | 572.5M | 689.7M | 781.2M | 16.3% | — | — | — | — |
| Op CF | 11.6M | 24.7M | 130.2M | 117.0M | 116.2% | 157.1M | — | — | — |
| Inv CF | -19.6M | -294.8M | -113.1M | 21.4M | — | — | — | — | — |
| Fin CF | 235.1M | 13.9M | -52.4M | -183.4M | — | — | — | — | — |
83% above its 52-week low and back above a rising 50-day average.
The Momentum score still reads 48: it weighs six months of price and earnings revisions, so it trails a turn like this.
Swung more than 84% of stocks we rank over the past year (71% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INSP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INSP | Inspire Medical Systems, Inc.(you) | $2.1B | 82 | Strong Buy |
| UFPT | UFP Technologies, Inc. | $2.3B | 80 | Strong Buy |
| CNMD | CONMED Corporation | $1.5B | 92 | Strong Buy |
| IRMD | IRADIMED CORPORATION | $1.1B | 75 | Buy |
| HAE | Haemonetics Corporation | $5.4B | 84 | Strong Buy |
| VREX | Varex Imaging Corporation | $782M | 76 | Buy |
| ITGR | Integer Holdings Corporation | $4.3B | 68 | Buy |
| BVS | Bioventus Inc. | $1.0B | 96 | Strong Buy |
| NEOG | Neogen Corporation | $2.7B | 57 | Hold |
| DCTH | Delcath Systems, Inc. | $500M | 78 | Buy |
Peer medians: ROE -31.5% · P/E 27.4x · Gross margin 62.6%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.